Elotuzumab plus lenalidomide/dexamethasone for relapsed/refractory multiple myeloma: Final overall survival results from the phase 3 ELOQUENT-2 trial

Dimopoulos M. A., Weisel K., Lonial S., White D., Moreau P., Mateos M., ...More

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, vol.19, no.10, 2019 (SCI-Expanded, Scopus) identifier

  • Publication Type: Article / Abstract
  • Volume: 19 Issue: 10
  • Publication Date: 2019
  • Doi Number: 10.1016/j.clml.2019.09.022
  • Journal Name: CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Keywords: elotuzumab, Overall survival, relapsed/refractory multiple myeloma
  • Ankara University Affiliated: Yes